GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Price-to-Owner-Earnings

Arecor Therapeutics (LSE:AREC) Price-to-Owner-Earnings : (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-14), Arecor Therapeutics's share price is £1.275. Arecor Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Arecor Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


LSE:AREC's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.65
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-14), Arecor Therapeutics's share price is £1.275. Arecor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.28. Therefore, Arecor Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-14), Arecor Therapeutics's share price is £1.275. Arecor Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.28. Therefore, Arecor Therapeutics's PE Ratio without NRI for today is At Loss.


Arecor Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Arecor Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Price-to-Owner-Earnings Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Arecor Therapeutics Semi-Annual Data
May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arecor Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Arecor Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arecor Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's Price-to-Owner-Earnings falls into.



Arecor Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Arecor Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.275/-0.24
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arecor Therapeutics  (LSE:AREC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Arecor Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Arecor Therapeutics (LSE:AREC) Business Description

Traded in Other Exchanges
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.

Arecor Therapeutics (LSE:AREC) Headlines

From GuruFocus